Asthma Treatment Advances Highlight Ongoing Global Access and Market Gaps

According to a recent LinkedIn post from Research Grid, the company is drawing attention to the ongoing global burden of asthma despite its treatable nature. The post cites World Asthma Day data indicating around 262 million people are affected and roughly 455,000 deaths occur annually, with low and middle income countries disproportionately impacted.

The post highlights structural barriers such as high inhaler costs, delayed diagnosis, limited specialist access, pollution exposure, and fragmented long-term care that push patients toward emergency treatment. It suggests these practical obstacles leave symptoms unmanaged for extended periods, increasing the likelihood of severe and preventable attacks.

Research Grid’s post also points to a pipeline of advanced therapies, referencing biologics such as Tezepelumab, longer-acting options like Depemokimab, combination inhalers evaluated in the MANDALA trial, and targeted agents including Dupilumab and Benralizumab. These developments are described as improving the potential standard of care for severe and complex asthma cases.

For investors, the content underscores sustained innovation and commercial opportunity across biologics, targeted immunology, and combination respiratory products, particularly for severe asthma segments. At the same time, the emphasis on access, diagnosis, and health-system capacity suggests that market growth may depend not only on clinical efficacy but also on pricing, reimbursement, and distribution models in emerging markets.

The post implies that companies positioned to address both innovation and access gaps could benefit from expanding global treatment uptake over time. It also indicates that data-driven research and real-world evidence on long-term outcomes and adherence may remain strategically important for stakeholders seeking to differentiate therapies and support broader adoption.